Lipopolysaccharide-induced ischemic tolerance is associated with increased levels of ceramide in brain and in plasma

Brain Research

Volumn 895, Issue 1-2, 2001, Pages 59-65

  Zimmermann, Carolin ^a   Ginis, Irene ^a   Furuya, Kazuhide ^a   Klimanis, Dace ^a   Ruetzler, Christl ^a   Spatz, Maria ^a   Hallenbeck, John M ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Ceramide; Ischemia; Lipopolysaccharide; Neuroprotection; Spontaneously hypertensive rat; Tolerance

Indexed keywords

BINDING PROTEIN; CERAMIDE; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOSE TIME EFFECT RELATION; LIPID BLOOD LEVEL; LIPID BRAIN LEVEL; LIPID METABOLISM; MEMBRANE TRANSPORT; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; TISSUE DISTRIBUTION;

4-CHLORO-7-NITROBENZOFURAZAN; ANIMALS; BLOOD-BRAIN BARRIER; BODY TEMPERATURE; BODY WEIGHT; BRAIN; BRAIN ISCHEMIA; CERAMIDES; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; FLUORESCENT DYES; INTERLEUKIN-6; ISCHEMIC PRECONDITIONING; LEUKOCYTES; LIPOPOLYSACCHARIDES; NEUROPROTECTIVE AGENTS; RATS; RATS, INBRED SHR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035937488     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(01)02028-5     Document Type: Article

References (48)

1. Ischemic preconditioning and brain tolerance: Temporal histological and functional outcomes, protein synthesis requirement, and interleukin-1 receptor antagonist and early gene expression
2. A rapid method of total lipid extraction and purification
3. LPS-induced delayed myocardial adaptation enhances acute preconditioning to optimize postischemic cardiac function
4. The nonspecific nature of endotoxin tolerance
5. Observations on the biosynthesis of rat brain ceramide and cerebroside in vivo
6. Glycosphingolipids of human plasma lipoproteins
7. Ischemic tolerance in brain
8. LPS pretreatment protects from hepatic ischemia/reperfusion
9. Cerebrovascular hemodynamics and ischemic tolerance: Lipopolysaccharide-induced resistance to focal cerebral ischemia is not due to changes in severity of the initial ischemic insult, but is associated with preservation of microvascular perfusion
10. In vivo metabolism of fluorescent ceramide in central nervous system myelin of adult rats
11. Tumor necrosis factor-alpha activates the sphingomyelin signal transduction pathway in a cell-free system
12. TNF-alpha pretreatment prevents subsequent activation of cultured brain cells with TNF-alpha and hypoxia via ceramide
13. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation
14. Inflammatory reactions at the blood-endothelial interface in acute stroke
15. Functions of ceramide in coordinating cellular responses to stress
16. Lipopolysaccharide pretreatment protects from renal ischemia/reperfusion injury: Possible connection to an interleukin-6-dependent pathway
17. Bacterial lipopolysaccharide has structural similarity to ceramide and stimulates ceramide-activated protein kinase in myeloid cells
18. Temporal profiles of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in the plasma and hypothalamic paraventricular nucleus after intravenous and intraperitoneal administration of lipopolysaccharide in the rat: Estimation by push-pull perfusion
19. Ceramide metabolism in brain
20. Ischemic tolerance phenomenon found in the brain
21. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling
22. Hypoxic preconditioning protects cultured neurons against hypoxic stress via TNF-alpha and ceramide
23. The role of ceramide in lipopolysaccharide (LPS)-induced signaling
24. Tumor necrosis factor: A cytokine involved in toxic effects of endotoxin
25. Ceramide: A novel second messenger
26. Neuroprotective signal transduction: Relevance to stroke
27. Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin
28. Sphingolipid biosynthesis de novo by rat hepatocytes in culture Ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion
29. Quantitation of free sphingosine in liver by high-performance liquid chromatography
30. Chromatogaphische mikromethode zur bestimmung der lipide im liquor cerebrospinalis
31. Molecular biology of septic shock
32. Regulation of the gene encoding tumor necrosis factor alpha (TNF-alpha) in the rat brain and pituitary in response in different models of systemic immune challenge
33. TNF-alpha pre-treatment induces protective effects against focal cerebral ischemia in mice
34. Lipid composition of the normal human brain: Gray matter, white matter, and myelin
35. Interleukin-1 mediates induction of tolerance to global ischemia in gerbil hippocampal CA1 neurons
36. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
37. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: Protection by fibroblast growth factor and sphingomyelinase deficiency
38. Induction of pro-inflammatory cytokine mRNAs in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat
39. Liquid chromatographic determination of sphinganine and sphingosine: Use of the free sphinganine-to-sphingosine ratio as a biomarker for consumption of fumonisins
40. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli
41. A single endotoxin challenge induces delayed myocardial protection against infarction
42. Separation and identification of cerebrosides in cerebrospinal fluid by gas chromatography-mass spectrometry
43. Sphingomyelin and ceramide mass assay
44. Dual role of tumor necrosis factor alpha in brain injury
45. Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats
46. Dose-dependence of bacterial lipopolysaccharide (LPS) effects on peak response and time course of the immune-endocrine host response in humans
47. Modulation of the free sphingosine levels in human neutrophils by phorbol esters and other factors
48. Ischemic preconditioning: Present position and future directions